Safety and Effectiveness of Short-Course AmBisome in the Treatment of Post–Kala-Azar Dermal Leishmaniasis: A Prospective Cohort Study in Bangladesh | Zendy

Margriet den Boer | Zendy; Asish Kumar Das | Zendy; Fatima Akhter | Zendy; Sakib Burza | Zendy; V. Ramesh | Zendy; BeNazir Ahmed | Zendy; Eduard E. Zijlstra | Zendy; Koert Ritmeijer | Zendy

Open Access

Safety and Effectiveness of Short-Course AmBisome in the Treatment of Post–Kala-Azar Dermal Leishmaniasis: A Prospective Cohort Study in Bangladesh

Author(s) -

Margriet den Boer,

Asish Kumar Das,

Fatima Akhter,

Sakib Burza,

V. Ramesh,

BeNazir Ahmed,

Eduard E. Zijlstra,

Koert Ritmeijer

Publication year - 2018

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciy172

Subject(s) - medicine , prospective cohort study , leishmaniasis , cohort , cohort study , surgery , immunology

A safe and effective short-course treatment regimen for post-kala-azar dermal leishmaniasis (PKDL) is considered essential for achieving and sustaining elimination of visceral leishmaniasis (VL) in the Indian subcontinent [1, 2]. Here, single-dose liposomal amphotericin B (AmBisome) has been adopted as a first-line regimen for VL; however the effectiveness and safety of AmBisome for PKDL has not been formally evaluated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research